Focusing on NSCLC, in Poland, NSCLC patients currently have access to the following ICIs and are only reimbursed for this indication: nivolumab and pembrolizumab (programmed cell death protein (PD-1) inhibitors) and atezolizumab (programmed cell death ligand 1 (PD-L1) inhibitor). This evidence concerns the gene CD274 and non-small cell lung carcinoma.